📣 VC round data is live. Check it out!
- Public Comps
- Bio-Rad Laboratories
Bio-Rad Laboratories Valuation Multiples
Discover Bio-Rad Laboratories' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Demant, Bruker, Shimadzu, Masimo and more.
Bio-Rad Laboratories Overview
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Founded
1975
HQ

Employees
7.5K
Website
Financials (LTM)
EV
$8B
Valuation Multiples
Start free trialBio-Rad Laboratories Financials
Bio-Rad Laboratories reported last 12-month revenue of $3B and EBITDA of $443M.
In the same LTM period, Bio-Rad Laboratories generated $1B in gross profit, $443M in EBITDA, and $259M in net income.
Revenue (LTM)
Bio-Rad Laboratories P&L
In the most recent fiscal year, Bio-Rad Laboratories reported revenue of $3B and EBITDA of $1B.
Bio-Rad Laboratories is profitable as of last fiscal year, with gross margin of 52%, EBITDA margin of 47%, and net margin of 29%.
Financial data powered by Morningstar, Inc.
Bio-Rad Laboratories Stock Performance
Bio-Rad Laboratories has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
Bio-Rad Laboratories' stock price is $305.76.
Bio-Rad Laboratories share price decreased by 1.7% in the last 30 days, and increased by 27.4% in the last year.
Bio-Rad Laboratories has an EPS (earnings per share) of $28.40.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | 0.2% | -1.7% | 9.7% | 27.4% | $28.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBio-Rad Laboratories Valuation Multiples
Bio-Rad Laboratories trades at 3.1x EV/Revenue multiple, and 18.1x EV/EBITDA.
EV / Revenue (LTM)
Bio-Rad Laboratories Financial Valuation Multiples
As of June 3, 2026, Bio-Rad Laboratories has market cap of $8B and EV of $8B.
Bio-Rad Laboratories has a P/E ratio of 31.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bio-Rad Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Bio-Rad Laboratories Margins & Growth Rates
Bio-Rad Laboratories decreased revenue by 0% and EBITDA by 65% in the last fiscal year.
In the most recent fiscal year, Bio-Rad Laboratories reported gross margin of 52%, EBITDA margin of 47%, and net margin of 29%.
Bio-Rad Laboratories Margins
Bio-Rad Laboratories Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bio-Rad Laboratories Operational KPIs
Bio-Rad Laboratories' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Bio-Rad Laboratories' Rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bio-Rad Laboratories' Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Bio-Rad Laboratories Competitors
Bio-Rad Laboratories competitors include Demant, Bruker, Shimadzu, Masimo, Horiba, Baxter International, Glaukos, Insulet, Asahi Intecc and Novanta.
Most Bio-Rad Laboratories public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.1x | 3.0x | 13.1x | 12.6x | |||
| 3.0x | 2.9x | 19.2x | 17.6x | |||
| 1.8x | 1.7x | 10.6x | 10.1x | |||
| 6.0x | 6.2x | 19.7x | 20.4x | |||
| 2.9x | 2.8x | 14.4x | 13.5x | |||
| 1.5x | 1.5x | 7.6x | 7.8x | |||
| 12.5x | 11.3x | (192.2x) | 1827.7x | |||
| 3.8x | 3.5x | 16.1x | 14.5x | |||
This data is available for Pro users. Sign up to see all Bio-Rad Laboratories competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Bio-Rad Laboratories
Bio-Rad Laboratories has acquired 6 companies to date.
Last acquisition by Bio-Rad Laboratories was on February 13th 2025. Bio-Rad Laboratories acquired Stilla Technologies for $225M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Bio-Rad Laboratories
| Description | Stilla Technologies is a Paris-headquartered biotechnology firm offering the Naica System, a digital PCR platform for genetic analysis in research, therapeutics, and omics applications. Leveraging microfluidic innovations, the system provides high-throughput multiplexing for detecting low-abundance targets in areas like oncology, infectious diseases, and prenatal testing across Europe and beyond. | Curiosity Diagnostics is a diagnostics company developing portable PCR systems for point-of-care testing. Its PCR ONE platform performs real-time amplification for pathogens like viruses and bacteria in under 20 minutes. Headquartered in Israel, the firm targets clinical labs and field deployments in remote areas. | DropWorks is a San Francisco-headquartered biotech firm developing microfluidic droplet nanoreactors for high-throughput digital PCR and assay automation. The portable systems deliver absolute quantification in under 30 minutes for research, diagnostics, and personalized medicine like cancer genotyping. DropWorks advances drug discovery and biomarker development through continuous-flow technology deployable in labs or field settings. | Celsee Diagnostics is a South San Francisco-based developer of microfluidic platforms for circulating tumor cell analysis. Its GENIUS system separates, detects, and retrieves rare cancer cells from whole blood without invasive biopsies. The technology supports downstream molecular analysis for personalized therapies and prognosis monitoring in oncology research. | |
| HQ Country | |||||
| HQ City | Paris | Warsaw | Boulder, CO | - | |
| Deal Date | 13 Feb 2025 | 3 Aug 2022 | 1 Oct 2021 | 9 Apr 2020 | |
| Valuation | $225M | $170M | $126M | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Bio-Rad Laboratories acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Bio-Rad Laboratories
Bio-Rad Laboratories has invested in 3 companies to date.
Latest investment by Bio-Rad Laboratories was on February 25th 2025. Bio-Rad Laboratories invested in Afynia Laboratories in their $5M Seed round (EV/Revenue multiple available to Pro users).
Latest Investments by Bio-Rad Laboratories
| Description | Afynia Laboratories is a Melbourne-based women's health company developing non-invasive diagnostics for endometriosis. Its saliva-based test detects biomarkers with 95 percent accuracy, addressing 190 million cases worldwide. Founded in 2020, Afynia partners with Australian universities for clinical trials targeting 2025 market launch. | Geneoscopy is a St. Louis-based diagnostics company that offers non-invasive stool RNA tests for colorectal cancer screening using computational biology. Its ColoSense assay detects gene expression changes in human RNA extracted from stool, achieving 92 percent sensitivity for CRC and 90 percent for advanced adenomas in pivotal trials. Geneoscopy expands its platform to other gastrointestinal diseases including IBD and pancreatic cancer screening. | Oxford Impedance Diagnostics researches bioimpedance tests to measure clinical biomarkers, aiming to lower healthcare costs and boost patient outcomes. |
| HQ Country | |||
| HQ City | - | Saint Louis, MO | Oxford |
| Deal Date | 25 Feb 2025 | 8 Jan 2025 | 25 Jul 2016 |
| Round | Seed | Series C | Seed |
| Raised | $5M | $105M | $3M |
| Investors | Bio-Rad Laboratories; Capital Angel Network; Gaingels; Impact America Fund; SOSV | Bio-Rad Laboratories; Granger Management LLC; Labcorp; Lightchain Capital; Mercy; Morningside; NT Investments; Petrichor Healthcare Capital Management; SINC Fund; Tri Locum Partners; Varia Ventures | Bio-Rad Laboratories; Oxford Science Enterprises |
| Valuation | undisclosed | undisclosed | undisclosed |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Bio-Rad Laboratories investments and their VC round multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bio-Rad Laboratories
| Who are competitors of Bio-Rad Laboratories? | Bio-Rad Laboratories main competitors include Demant, Bruker, Shimadzu, Masimo, Horiba, Baxter International, Glaukos, Insulet, Asahi Intecc, Novanta. |
See public comps similar to Bio-Rad Laboratories
Lists including Bio-Rad Laboratories
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




